Effect of BooZLiv in patients with alcoholic liver disease

Safety and efficacy of BooZLiv in patients with alcoholic liver disease : An open-label, randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/08/044978

Enrollment

Registered

2022-08-26

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K709- Alcoholic liver disease, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adults aged over 18 years with the evidence of alcoholic liver disease (ALD) based on a thorough history, physical examination, and laboratory tests and all of the following: 2.Chronic alcohol intake, Identified with AUDIT(Alcohol Use Disorder Inventory Test) Questionnaire 3.Active alcohol use until 4 weeks prior to presentation 4.ALT and AST elevated >1.5 times the upper limit of normal Over 1.5 ratio of AST to ALT

Exclusion criteria

Exclusion criteria: 1.Severe alcoholic hepatitis with cirrhosis 2.Severe renal impairment 3.Participants with active viral hepatitis 4.Pregnant, attempting to conceive, or lactating women

Design outcomes

Primary

Measure	Time frame
Liver function test Complete blood count Prothrombin time MELD Score Timepoint: baseline to 30th day ,60th day and 90th day	—

Secondary

Measure	Time frame
Adverse events SF-12 QuestionnaireTimepoint: After the completion of treatment	—

Countries

India

Contacts

Public ContactDR Vijayakumar TM

SRM College of Pharmacy

priyadha@srmist.edu.in9787402050

Outcome results